fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Piroxicam

All products: general benefit

Teva-Piroxicam · DIN 00695718 · 10 mg · capsule

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Teva-Piroxicam · DIN 00695718 Manufacturer: Teva Canada Limited; listing date 1996-10-01 Health Canada: Marketed since 2015-07-15 · brand TEVA-PIROXICAM · ATC M01AC01 PIROXICAM · form Capsule · route Oral · ingredients PIROXICAM 10 MG · company Teva canada limited · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Teva-Piroxicam: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4426). What the ministry pays, not the patient.

Ministry pays: $0.4426 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00695718)

Source record
DIN 00695718: Teva-Piroxicam Raw flags: sec3=Y Item: 280804038; group id 393; item number 0941; lccId None; manufacturer id TEV Source form: Cap; strength: 10mg Recorded listing: General benefit Source prices (unrounded): $0.4426; ministry $0.4426 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00695718 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=6813 Therapeutic Notes (formulary) NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Apo-Piroxicam · DIN 00642886 · $0.4426 Feldene · DIN 00525596 · not recorded
Shortage status: discontinued (August 28, 2025, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00695718
Shortage record checked October 6, 2026

Other products in the same Health Canada class (M01A, M01AC): coverage varies; not interchangeable

  • Meloxicam (Mobicox): general benefit, not a benefit
  • Diclofenac (Voltaren): general benefit, not a benefit
  • Diclofenac + misoprostol (Arthrotec 50): general benefit
  • Flurbiprofen (Ansaid): general benefit, not a benefit
  • Ibuprofen (Motrin): general benefit, not a benefit
  • Indomethacin (Indocid): general benefit, not a benefit

12 more in the class list below

Other drugs in the same formulary class (28:08:04 Nonsteroidal Anti-Inflammatory Agents) and how they are covered

Matched class: 28:08:04 Nonsteroidal Anti-Inflammatory Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DICLOFENAC SODIUM & MISOPROSTOL Some products covered without a code (check the product listing): DICLOFENAC SODIUM, FLURBIPROFEN, IBUPROFEN, INDOMETHACIN, KETOPROFEN, MEFENAMIC ACID, MELOXICAM, NAPROXEN, SULINDAC, TIAPROFENIC ACID 28:08:04 Nonsteroidal Anti-Inflammatory Agents

MELOXICAM

· 14 products · Listed, not a benefit (2), General benefit (12) · strengths: 7.5mg, 15mg · Tab

DICLOFENAC SODIUM

· 19 products · Listed, not a benefit (3), General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 25mg, 50mg, 75mg, 100mg, 1.5% W/W · Ent Tab, LA Tab, Sup, Top Sol

DICLOFENAC SODIUM & MISOPROSTOL

· 6 products · General benefit · strengths: 50mg & 200mcg, 75mg & 200mcg · Tab

FLURBIPROFEN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 50mg, 100mg · Tab

IBUPROFEN

· 11 products · Listed, not a benefit (3), General benefit (7), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 200mg, 300mg, 400mg, 600mg · Tab

INDOMETHACIN

· 10 products · Listed, not a benefit (4), General benefit (6) · strengths: 25mg, 50mg, 100mg · Cap, Sup

KETOPROFEN

· 9 products · General benefit (4), Listed, not a benefit (5) · strengths: 50mg, 100mg, 200mg · Cap, Ent Tab, LA Tab

MEFENAMIC ACID

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 250mg · Cap

NAPROXEN

· 21 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (8), Listed, not a benefit (4) · strengths: 250mg, 375mg, 500mg, 25mg/mL, 125mg · Ent Tab, O/L, Tab

SULINDAC

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 150mg, 200mg · Tab

TIAPROFENIC ACID

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 200mg, 300mg · Tab

CELECOXIB

· 36 products · Limited Use, codes 316, 317 · strengths: 100mg, 200mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 28:08:04 and 6 more
Full class listing Related classes: 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:04 Antidepressants, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: the symptomatic treatment of
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. MELOXICAM · Listed, not a benefit (2), General benefit (12) INDICATIONS AND CLINICAL USE pms-MELOXICAM (meloxicam) is indicated for the symptomatic treatment of:  Rheumatoid arthritis in adults, and  Painful osteoarthritis (arthrosis, degenerative joint disease) in adults Throughout this document, the term NSAIDs refers to both non-selective NSAIDs and selective COX-2 inhibitor NSAIDs, unless otherwise indicated. PM: https://pdf.hres.ca/dpd_pm/00064407.PDF; date January 19, 2022; DIN 02248267; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
1 INDICATIONS APO-PIROXICAM (piroxicam) is indicated for the symptomatic treatment of: • rheumatoid arthritis, • osteoarthritis (degenerative joint disease) and • ankylosing spondylitis. Throughout this document, the term NSAIDs refers to both non-selective NSAIDs and selective COX-2 inhibitor NSAIDs, unless otherwise indicated. For patients with an increased risk of developing CV and/or GI adverse events, other management strategies that do NOT include the use of NSAIDs should be considered first. (See 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS). Use of APO-PIROXICAM (piroxicam) should be limited to the lowest effective dose for the shortest possible duration of treatment in order to minimize the potential risk for cardiovascular or gastrointestinal adverse events. (See 2 CONTRAINDICATIONS and 7 WARNINGS AND PRECAUTIONS). APO-PIROXICAM (piroxicam), as a NSAID, does NOT treat clinical disease or prevent its progression. APO-PIROXICAM (piroxicam), as a NSAID, only relieves symptoms and decreases inflammation for as long as the patient continues to take it. 1.1 Pediatrics (< 16 years of age): Based on the data sub… https://pdf.hres.ca/dpd_pm/00071325.PDF PM date: MAY 16, 2023 Source product: APO PIROXICAM CAP 10MG; DIN 00642886; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Piroxicam · DIN 00695718 Shortage status: discontinued (2025-08-28, reported by TEVA CANADA LIMITED); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=00695718

Check this DIN again